Investment Opportunity
Cardio AI is revolutionizing cardiovascular medicine through a unified multi-agent AI system that combines cutting-edge risk prediction, real-time patient monitoring, and personalized care recommendations. Our platform addresses the $183B cardiovascular care market with innovative technology that reduces hospitalizations by 30%, improves outcomes by 25%, and decreases healthcare costs by up to 40%.
- FDA breakthrough device designation pathway
- Strategic partnerships with 3 major health systems
- Validated risk models with AUC >0.82 across all calculators
- 18-month runway to commercialization
- Experienced founding team from Stanford, Mayo Clinic, Google Health
Our Technology Platform
Unified Multi-Agent System
8 specialized AI agents working in concert to deliver comprehensive cardiovascular care management and clinical decision support.
5 Risk Calculators
Deep learning models for AMI, Heart Failure, Stroke, Sudden Cardiac Death, and Atrial Fibrillation with superior predictive accuracy.
IoMT-RPM Integration
Real-time monitoring through wearables and medical devices, processing 1M+ data points daily for early intervention.
Three-Tier Confidence
Proprietary oversight framework ensuring clinical safety while maximizing AI autonomy for time-critical decisions.
8 Specialized AI Agents
Massive Market Opportunity
Addressable Market Segments
Use of Funds ($5M Seed Round)
18-Month Commercialization Roadmap
• Initiate 3-site clinical validation study (n=5,000 patients)
• Submit FDA pre-submission meeting request
• Expand engineering team to 12 FTEs
• FDA pre-submission meeting and feedback incorporation
• Complete ISO 13485 QMS implementation
• Launch pilot with 2 partner health systems
• Submit FDA 510(k) application
• Publish validation results in peer-reviewed journals
• Scale pilots to 10 sites, 50,000 patients
• Commercial launch with 5 anchor customers
• Series A fundraising ($20M target)
• Achieve 100,000 monitored patients milestone
Competitive Advantages
Financial Projections
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Monitored Patients | 50,000 | 250,000 | 1,000,000 |
| Revenue (PMPM $40) | $24M | $120M | $480M |
| Gross Margin | 75% | 82% | 85% |
| EBITDA | $12M | $24M | $168M |
Current Traction
Strategic Partnerships
- ✓ MOU with 3 major health systems (combined 18M lives)
- ✓ Partnership with leading wearables manufacturer
- ✓ Academic Collaborations: Stanford Medicine, Weill Cornell Medicine, Harvard Medicine
- ✓ Advisory board: 8 prominent cardiologists
Technical Milestones
- ✓ Platform MVP complete and tested
- ✓ Risk models validated (retrospective n=50,000)
- ✓ IoMT integration with 12+ device types
- ✓ HIPAA compliance and SOC 2 Type II certification
